Skip to main content
Vcanbio Cell & Gene Engineering Corp., Ltd logo

Vcanbio Cell & Gene Engineering Corp., Ltd — Investor Relations & Filings

Ticker · 600645 ISIN · CNE000000545 LEI · 300300FLWFDJPQYVAZ24 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 2,580 across all filing types
Latest filing 2013-06-06 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 600645

About Vcanbio Cell & Gene Engineering Corp., Ltd

https://www.vcanbio.com/

Vcanbio Cell & Gene Engineering Corp., Ltd. specializes in the fields of cell therapy, gene technology, and precision medicine. The company operates a comprehensive business model centered on the storage of hematopoietic and mesenchymal stem cells, providing long-term bio-banking services for cord blood and other biological tissues. Its technical portfolio includes advanced genetic testing services, such as prenatal screening and oncology diagnostics, alongside the development of cell-based therapeutic products. Vcanbio maintains a network of specialized laboratories and storage facilities to support clinical research and personalized healthcare applications. The organization focuses on translating biotechnological advancements into clinical solutions, emphasizing quality control in cell processing and genomic analysis to serve the evolving needs of the regenerative medicine and diagnostic sectors.

Recent filings

Filing Released Lang Actions
第七届董事会第二十六次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at a board meeting of Zhongyuan Xiehe Stem Cell Bioengineering Co., Ltd. It details voting results on related party transactions and mentions that these matters will be submitted to the 2012 annual shareholders' meeting for approval. The document is short (914 characters) and primarily reports on board decisions and voting outcomes rather than providing detailed financial data or full reports. It does not contain financial statements or comprehensive management discussion. Therefore, it fits best under the category of Board/Management Information (MANG), which covers announcements of board decisions and management matters.
2013-06-06 Chinese
关于解租现有办公场所并承租新办公场所的关联交易公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding a related-party transaction involving the leasing of new office premises by the company. It details the transaction terms, related parties, pricing policy, approval procedures, and independent directors' opinions. It is not a financial report, earnings release, or management discussion. It is a regulatory announcement about a corporate transaction that requires shareholder approval. The document length is 3384 characters, which is relatively short and consistent with an announcement rather than a full report. There is no indication that this is a report publication announcement or a certification. The content fits best with a Regulatory Filings (RNS) classification, as it is a general regulatory announcement about a related-party transaction and does not fit other more specific categories.
2013-06-06 Chinese
关于公司与天津开发区德源投资发展有限公司签订《借款合同》补充协议书的关联交易公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding a supplemental agreement to a loan contract between the company and its controlling shareholder, which constitutes a related party transaction. It details the terms of the loan extension, the approval process by the board and shareholders, and includes independent directors' opinions. The document is a formal disclosure of a financing-related transaction but does not contain financial statements or comprehensive financial data. It is not a full financial report, earnings release, or management discussion. The content fits best under Capital/Financing Update (CAP) as it updates on the company's financing activities and capital structure changes through a related party loan agreement.
2013-06-06 Chinese
2012年年度股东大会会议通知
AGM Information Classification · 95% confidence The document is a notice for the 2012 Annual General Meeting (AGM) of the company, detailing the meeting date, agenda items including the review of the 2012 annual report, board and supervisory reports, financial statements, profit distribution plan, auditor appointment, and other corporate matters. It also includes procedural information about attendance, voting, and proxy authorization. The document does not contain the actual annual report or financial statements but rather serves as an announcement and invitation to the AGM. The document length is relatively short (2613 characters), and it explicitly states the meeting agenda and voting procedures. Therefore, this document fits the category of AGM Information (AGM-R) rather than the Annual Report (10-K) or any other category.
2013-06-06 Chinese
有限售条件的流通股上市流通申请的核查意见书
Capital/Financing Update Classification · 95% confidence The document is a detailed verification opinion letter from a sponsoring securities company regarding the application for listing of restricted circulating shares of Zhongyuan Xiehe Stem Cell Bioengineering Co., Ltd. It discusses the company's equity reform plan, shareholder commitments, changes in shareholding, and the specifics of the restricted shares being listed for circulation. The document includes legal and procedural details about shareholding changes, judicial auctions, and compliance with regulatory requirements. It is not a financial report, earnings release, or management discussion, but rather a formal verification and opinion related to a capital market transaction involving share circulation. This fits the category of a Capital/Financing Update (CAP), as it concerns updates on share capital structure and listing of restricted shares.
2013-05-16 Chinese
有限售条件的流通股上市公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the listing of restricted tradable shares (有限售条件的流通股上市公告) for the company 中源协和干细胞生物工程股份公司. It details the number of shares to be listed, the date of listing, background on the share reform, shareholder commitments, changes in shareholding, and related approvals. The document is a formal public announcement about the listing of shares that were previously restricted, including historical context and compliance confirmations. It does not contain financial statements, audit opinions, or detailed financial performance data. It is not a report like an Annual Report (10-K), Interim Report (IR), or Earnings Release (ER). It is also not a regulatory filing in the sense of officer certifications or legal proceedings. The document is a specific announcement about the listing of restricted shares, which fits best under the category of Regulatory Filings (RNS) as a general regulatory announcement that does not fit other categories more specifically. The document length is 3543 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, the best classification is Regulatory Filings (RNS).
2013-05-16 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.